µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2024-2031³â)
Digital Biomarkers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â ÃÖ±Ù ¼¼°è µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Á¶»ç º¸°í¼¸¦ ¹ßÇ¥ÇÏ¿© ÁÖ¿ä µ¿ÀÎ, »õ·Î¿î µ¿Çâ, ±âȸ ¹× °úÁ¦¸¦ Æ÷ÇÔÇÑ ÁÖ¿ä ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®À» Á¦°øÇß½À´Ï´Ù. ÀÌ º¸°í¼´Â ½ÃÀå »óȲÀ» ÀÚ¼¼È÷ ÀÌÇØÇϰí ÀÌÇØ°ü°èÀÚµéÀÌ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð(2024³â) : 27¾ï ´Þ·¯
¿¹»ó ½ÃÀå ±Ô¸ð(2031³â) : 106¾ï ´Þ·¯
¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2024-2031³â) : 21.8%
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Á¶»ç ¹üÀ§
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡´Â ¿þ¾î·¯ºí, ÈÞ´ë¿ë, ¼Òȱâ, ÀÓÇöõÆ® ±â¼ú µî µðÁöÅÐ ±â±â¸¦ ÅëÇØ ¼öÁýµÇ´Â Á¤·®Àû, ºñħ½ÀÀû, °´°üÀû, Áö¼ÓÀû »ý¸®Àû, ÇൿÇÐÀû ÃøÁ¤ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸¶Ä¿´Â ½ÇÁ¦ Áúº´ ÁøÇà, Ä¡·á È¿°ú ¹× ȯÀÚ ¹ÝÀÀ¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀº ¿þ¾î·¯ºí ±â¼ú, ¸ð¹ÙÀÏ °Ç° ¿ëµµ, µðÁöÅÐ °Ç° µµ±¸¿¡¼ »ý¼ºµÈ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ´Â AI ¾Ë°í¸®ÁòÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ÃËÁøµÉ °ÍÀÔ´Ï´Ù. µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ßÀüÀº °³ÀÎ ¸ÂÃãÇü ÀÇ·á, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ, Áúº´ Á¶±â ¹ß°ß¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ ÀÇ·á ¼ºñ½º Á¦°ø°ú ÀÓ»ó½ÃÇèÀÇ È¿À²¼ºÀ» Å©°Ô Çâ»ó½Ãų °ÍÀÔ´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :
°³ÀÎÈµÈ ¿ø°Ý ȯÀÚ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä´Â µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁøÁ¦À̸ç, °¡Ä¡ ±â¹Ý ÀÇ·á ¸ðµ¨·Î ÀüȯÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µ¿ÀÎÀÔ´Ï´Ù. »ý¸®Àû ¸Å°³º¯¼ö¿Í ȯ°æÀû ¿äÀÎÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇÏ¿© Á¾ÇÕÀûÀÎ °Ç° »óŸ¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ¾î ¸ÂÃãÇü Ä¡·á °èȹ°ú ´õ ³ªÀº Áúº´ °ü¸®¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, AI ¹× ¸Ó½Å·¯´×(ML)°ú °°Àº ÷´Ü ±â¼úÀÇ »ç¿ëÀº ½Ç½Ã°£ µ¥ÀÌÅ͸¦ ¼öÁýÇÏ°í ½Ã¼³ ¹æ¹®À» ÃÖ¼ÒÈÇÏ¸ç µ¥ÀÌÅÍ Ç°ÁúÀ» Çâ»ó½ÃÄÑ ÀÓ»ó½ÃÇèÀÇ Á¤È®¼º°ú ȯÀÚ Áß½ÉÁÖÀǸ¦ °ÈÇÕ´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :
º¹ÀâÇÑ »óȯ Á¦µµ¿Í µðÁöÅÐ Ä¡·áÁ¦¿¡ ´ëÇÑ ÁøÈÇÏ´Â ±ÔÁ¦ µîÀÇ ¹®Á¦°¡ ÀÖ½À´Ï´Ù. »óȯ ü°è¸¦ µÑ·¯½Ñ ºÒÈ®½Ç¼ºÀº µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Ã¤ÅÃÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. À¯·´ÀÇ GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤)(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤)À̳ª ¹Ì±¹ÀÇ HIPAA¿Í °°Àº ¾ö°ÝÇÑ µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹ý±Ô¸¦ ÁؼöÇϱâ À§Çؼ´Â Áö¿ª °£ ±ÔÁ¦ Áؼö¿¡ ´ëÀÀÇÒ ¼ö Àִ źźÇÑ ¸®¼Ò½º°¡ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ´Ù¾çÇÑ ÇコÄɾî ȯ°æ¿¡¼ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿¸¦ Ç¥ÁØÈÇÏ´Â °ÍÀº º¹ÀâÇϸç, ÀÌ´Â µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °¡Ä¡¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ :
ºí·ÏüÀÎÀ» Ȱ¿ëÇØ µ¥ÀÌÅÍ º¸¾ÈÀ» °ÈÇϰí ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü, ±â¼ú ±â¾÷, ¿¬±¸ ±â°ü°ú Çù·ÂÇϸé Å« ºñÁî´Ï½º ±âȸ¸¦ âÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ºí·ÏüÀÎ ±â¼úÀº ¹Î°¨ÇÑ ÀÇ·á µ¥ÀÌÅ͸¦ Ä§ÇØ·ÎºÎÅÍ º¸È£Çϰí, ÆÄÆ®³Ê½ÊÀ» ÅëÇØ °·ÂÇÑ ¹ÙÀÌ¿À¸¶Ä¿ °³¹ßÀ» °¡¼ÓÈÇϰí Çõ½ÅÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Ä¡·á Àü·«À» ÃÖÀûÈÇϰí ÀÓ»ó °á°ú¸¦ °³¼±ÇÔÀ¸·Î½á Á¤¹ÐÀǷḦ Áö¿øÇÒ ¼ö ÀÖ½À´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®µé
¼¼°è µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿°¡ °¡Àå ¸¹ÀÌ µµÀԵǰí ÀÖ´Â Ä¡·á ºÐ¾ß´Â?
±ÔÁ¦¿Í Á¤Ã¥ÀÌ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ¾îµð¿¡ ÀÖÀ¸¸ç, °æÀïÀ» À¯ÁöÇϱâ À§ÇØ ¾î¶² Àü·«À» äÅÃÇϰí Àִ°¡?
¼¼°è µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ »õ·Î¿î Æ®·»µå¿Í ¹Ì·¡ Àü¸ÁÀº?
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¼ºÀå ¾ïÁ¦¿äÀÎ
±âȸ
ÁÖ¿ä µ¿Çâ
°Å½Ã°æÁ¦ ¿äÀÎ
¼¼°èÀÇ ºÎ¹®º° Àü¸Á
¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
¼¼°èÀÇ ÀÇ·áºñ ÁöÃâ Àü¸Á
COVID-19ÀÇ ¿µÇ⠺м®
¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ÀÖ´Â ÀλçÀÌÆ®
Á¦Ç° äÅà ºÐ¼®
±â¼ú Æò°¡
±ÔÁ¦ »óȲ
°ø±Þ¸Á ºÐ¼®
ÁÖ¿ä °Å·¡¿Í ÇÕº´
PESTLE ºÐ¼®
PorterÀÇ Five Forces ºÐ¼®
Á¦4Àå °¡°Ý ºÐ¼® 2024³â
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
Ä¡·á ¿µ¿ª °¡°Ý¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎ
ÄÄÆ÷³ÍÆ®º° °¡°Ý ºÐ¼®
Áö¿ªº° °¡°Ý°ú Ä¡·á ¿µ¿ª ¼±È£
Á¦5Àå ¼¼°èÀÇ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â)°ú ¿¹Ãø(2024³â-2031³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ¼ö·® ¿¹Ãø
½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå·ü
Àý´ëÀûÀÎ$±âȸ
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, 2019³â-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, 2024³â-2031³â
¼¼°èÀÇ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ÄÄÆ÷³ÍÆ®º°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð¿Í ¼ö·® ºÐ¼® : ÄÄÆ÷³ÍÆ®º°, 2019³â-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·® ºÐ¼®°ú ¿¹Ãø : ÄÄÆ÷³ÍÆ®º°, 2024³â-2031³â
µ¥ÀÌÅÍ ¼öÁý Åø
¿þ¾î·¯ºí µð¹ÙÀ̽º
Implantable
¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç
±âŸ
µ¥ÀÌÅÍ ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÄÄÆ÷³ÍÆ®º°
¼¼°èÀÇ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : Ä¡·á ¿µ¿ªº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : Ä¡·á ¿µ¿ªº°, 2019³â-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Ä¡·á ¿µ¿ªº°, 2024³â-2031³â
½ÉÇ÷°ü ¹× ´ë»çÁúȯ(CVMD)
½Å°æ ÅðÇ༺ Áúȯ
´ç´¢º´
È£Èí±âÁúȯ
¼ö¸é ¹× ¿îµ¿Àå¾Ö
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Ä¡·á ¿µ¿ªº°
¼¼°èÀÇ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : Clinical Practiceº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : Clinical Practiceº°, 2019³â-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Clinical Practiceº°, 2024³â-2031³â
Áø´Ü¿ë µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ¸ð´ÏÅ͸µ
¿¹Ãø ¹× ¿¹ÈÄ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Clinical Practiceº°
¼¼°èÀÇ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ÃÖÁ¾»ç¿ëÀÚº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2024³â-2031³â
ÇコÄÉ¾î ¼ÒºñÀÚ
ÀÇ·á Á¦°øÀÚ
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
Á¦6Àå ¼¼°èÀÇ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : Áö¿ªº°
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : Áö¿ªº°, 2019³â-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°, 2024³â-2031³â
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ªº°
Á¦7Àå ºÏ¹Ì µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â) ¹× ¿¹Ãø(2024³â-2031³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ½ÃÀ庰, 2019³â-2023³â
±¹°¡º°
ÄÄÆ÷³ÍÆ®º°
Ä¡·á ¿µ¿ªº°
Clinical Practiceº°
ÃÖÁ¾»ç¿ëÀÚº°
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°, 2024³â-2031³â
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·® ºÐ¼®°ú ¿¹Ãø : ÄÄÆ÷³ÍÆ®º°, 2024³â-2031³â
µ¥ÀÌÅÍ ¼öÁý Åø
¿þ¾î·¯ºí µð¹ÙÀ̽º
Implantable
¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç
±âŸ
µ¥ÀÌÅÍ ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Ä¡·á ¿µ¿ªº°, 2024³â-2031³â
½ÉÇ÷°ü ¹× ´ë»çÁúȯ(CVMD)
½Å°æ ÅðÇ༺ Áúȯ
´ç´¢º´
È£Èí±âÁúȯ
¼ö¸é ¹× ¿îµ¿Àå¾Ö
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Clinical Practiceº°, 2024³â-2031³â
Áø´Ü¿ë µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ¸ð´ÏÅ͸µ
¿¹Ãø ¹× ¿¹ÈÄ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2024³â-2031³â
ÇコÄÉ¾î ¼ÒºñÀÚ
ÀÇ·á Á¦°øÀÚ
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦8Àå À¯·´ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â)°ú ¿¹Ãø(2024³â-2031³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ½ÃÀ庰, 2019³â-2023³â
±¹°¡º°
ÄÄÆ÷³ÍÆ®º°
Ä¡·á ¿µ¿ªº°
Clinical Practiceº°
ÃÖÁ¾»ç¿ëÀÚº°
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°, 2024³â-2031³â
µ¶ÀÏ
ÇÁ¶û½º
¿µ±¹
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
·¯½Ã¾Æ
ÅÍŰ
±âŸ À¯·´
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·® ºÐ¼®°ú ¿¹Ãø : ÄÄÆ÷³ÍÆ®º°, 2024³â-2031³â
µ¥ÀÌÅÍ ¼öÁý Åø
¿þ¾î·¯ºí µð¹ÙÀ̽º
Implantable
¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç
±âŸ
µ¥ÀÌÅÍ ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Ä¡·á ¿µ¿ªº°, 2024³â-2031³â
½ÉÇ÷°ü ¹× ´ë»ç Áúȯ(CVMD)
½Å°æ ÅðÇ༺ Áúȯ
´ç´¢º´
È£Èí±âÁúȯ
¼ö¸é ¹× ¿îµ¿Àå¾Ö
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Clinical Practiceº°, 2024³â-2031³â
Áø´Ü¿ë µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ¸ð´ÏÅ͸µ
¿¹Ãø ¹× ¿¹ÈÄ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2024³â-2031³â
ÇコÄÉ¾î ¼ÒºñÀÚ
ÀÇ·á Á¦°øÀÚ
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦9Àå µ¿¾Æ½Ã¾Æ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â)°ú ¿¹Ãø(2024³â-2031³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ½ÃÀ庰, 2019³â-2023³â
±¹°¡º°
ÄÄÆ÷³ÍÆ®º°
Ä¡·á ¿µ¿ªº°
Clinical Practiceº°
ÃÖÁ¾»ç¿ëÀÚº°
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°, 2024³â-2031³â
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·® ºÐ¼®°ú ¿¹Ãø : ÄÄÆ÷³ÍÆ®º°, 2024³â-2031³â
µ¥ÀÌÅÍ ¼öÁý Åø
¿þ¾î·¯ºí µð¹ÙÀ̽º
Implantable
¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç
±âŸ
µ¥ÀÌÅÍ ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Ä¡·á ¿µ¿ªº°, 2024³â-2031³â
½ÉÇ÷°ü ¹× ´ë»çÁúȯ(CVMD)
½Å°æ ÅðÇ༺ Áúȯ
´ç´¢º´
È£Èí±âÁúȯ
¼ö¸é ¹× ¿îµ¿Àå¾Ö
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Clinical Practiceº°, 2024³â-2031³â
Áø´Ü¿ë µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ¸ð´ÏÅ͸µ
¿¹Ãø ¹× ¿¹ÈÄ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2024³â-2031³â
ÇコÄÉ¾î ¼ÒºñÀÚ
ÀÇ·á Á¦°øÀÚ
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦10Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â) ¹× ¿¹Ãø(2024³â-2031³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ½ÃÀ庰, 2019³â-2023³â
±¹°¡º°
ÄÄÆ÷³ÍÆ®º°
Ä¡·á ¿µ¿ªº°
Clinical Practiceº°
ÃÖÁ¾»ç¿ëÀÚº°
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°, 2024³â-2031³â
Àεµ
µ¿³²¾Æ½Ã¾Æ
È£ÁÖ
±âŸ ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·® ºÐ¼®°ú ¿¹Ãø : ÄÄÆ÷³ÍÆ®º°, 2024³â-2031³â
µ¥ÀÌÅÍ ¼öÁý Åø
¿þ¾î·¯ºí µð¹ÙÀ̽º
Implantable
¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç
±âŸ
µ¥ÀÌÅÍ ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Ä¡·á ¿µ¿ªº°, 2024³â-2031³â
½ÉÇ÷°ü ¹× ´ë»çÁúȯ(CVMD)
½Å°æ ÅðÇ༺ Áúȯ
´ç´¢º´
È£Èí±âÁúȯ
¼ö¸é ¹× ¿îµ¿Àå¾Ö
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Clinical Practiceº°, 2024³â-2031³â
Áø´Ü¿ë µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ¸ð´ÏÅ͸µ
¿¹Ãø ¹× ¿¹ÈÄ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2024³â-2031³â
ÇコÄÉ¾î ¼ÒºñÀÚ
ÀÇ·á Á¦°øÀÚ
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦11Àå ¶óÆ¾¾Æ¸Þ¸®Ä« µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â)°ú ¿¹Ãø(2024³â-2031³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ½ÃÀ庰, 2019³â-2023³â
±¹°¡º°
ÄÄÆ÷³ÍÆ®º°
Ä¡·á ¿µ¿ªº°
Clinical Practiceº°
ÃÖÁ¾»ç¿ëÀÚº°
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°, 2024³â-2031³â
ºê¶óÁú
¸ß½ÃÄÚ
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·® ºÐ¼®°ú ¿¹Ãø : ÄÄÆ÷³ÍÆ®º°, 2024³â-2031³â
µ¥ÀÌÅÍ ¼öÁý Åø
¿þ¾î·¯ºí µð¹ÙÀ̽º
Implantable
¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç
±âŸ
µ¥ÀÌÅÍ ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Ä¡·á ¿µ¿ªº°, 2024³â-2031³â
½ÉÇ÷°ü ¹× ´ë»çÁúȯ(CVMD)
½Å°æ ÅðÇ༺ Áúȯ
´ç´¢º´
È£Èí±âÁúȯ
¼ö¸é ¹× ¿îµ¿Àå¾Ö
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Clinical Practiceº°, 2024³â-2031³â
Áø´Ü¿ë µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ¸ð´ÏÅ͸µ
¿¹Ãø ¹× ¿¹ÈÄ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2024³â-2031³â
ÇコÄÉ¾î ¼ÒºñÀÚ
ÀÇ·á Á¦°øÀÚ
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2023³â) ¹× ¿¹Ãø(2024³â-2031³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ½ÃÀ庰, 2019³â-2023³â
±¹°¡º°
ÄÄÆ÷³ÍÆ®º°
Ä¡·á ¿µ¿ªº°
Clinical Practiceº°
ÃÖÁ¾»ç¿ëÀÚº°
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°, 2024³â-2031³â
GCC ±¹°¡
ÀÌÁýÆ®
³²¾ÆÇÁ¸®Ä«°øÈ±¹
ºÏ¾ÆÇÁ¸®Ä«
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·® ºÐ¼®°ú ¿¹Ãø : ÄÄÆ÷³ÍÆ®º°, 2024³â-2031³â
µ¥ÀÌÅÍ ¼öÁý Åø
¿þ¾î·¯ºí µð¹ÙÀ̽º
Implantable
¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç
±âŸ
µ¥ÀÌÅÍ ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Ä¡·á ¿µ¿ªº°, 2024³â-2031³â
½ÉÇ÷°ü ¹× ´ë»çÁúȯ(CVMD)
½Å°æ ÅðÇ༺ Áúȯ
´ç´¢º´
È£Èí±âÁúȯ
¼ö¸é ¹× ¿îµ¿Àå¾Ö
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Clinical Practiceº°, 2024³â-2031³â
Áø´Ü¿ë µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ¸ð´ÏÅ͸µ
¿¹Ãø ¹× ¿¹ÈÄ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿
±âŸ
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2024³â-2031³â
ÇコÄÉ¾î ¼ÒºñÀÚ
ÀÇ·á Á¦°øÀÚ
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦13Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
½ÃÀå ±¸Á¶
½ÃÀ庰 °æÀï °µµ ¸ÅÇÎ
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
ActiGraph LLC
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
AliveCor Inc.
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Koneksa Health
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Altoida Inc.
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Biogen
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Empatica Inc.
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Vivo Sense
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
IXICO plc
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Aural Analytic
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Huma
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Sonde Health, Inc.
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Akili Interactive Labs, Inc.
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Cambridge Cognition Ltd.
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Dassault Systemes(Medidata)
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Shimmer
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Feel Therapeutics
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Clario
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Imagene AI
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Brainomix
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Kinsa Inc.
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Pfizer Hellas S.A.
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Human API
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Evidation Health, Inc.
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Varily
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
electronRx
°³¿ä
ºÎ¹®°ú Á¦Ç°
ÁÖ¿ä À繫 Á¤º¸
½ÃÀå µ¿Çâ
½ÃÀå Àü·«
Á¦14Àå ºÎ·Ï
Á¶»ç ¹æ¹ý
Á¶»ç ÀüÁ¦
µÎÀÚ¾î ¹× ¾à¾î
LSH
Persistence Market Research has recently released a comprehensive report on the global Digital Biomarkers Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report delivers a detailed understanding of the market landscape, empowering stakeholders to make well-informed decisions.
Key Insights:
Digital Biomarkers Market Size (2024E): US$2.7 Bn
Projected Market Value (2031F): US$10.6 Bn
Global Market Growth Rate (CAGR 2024 to 2031): 21.8%
Digital Biomarkers Market - Report Scope:
The Digital Biomarkers Market encompasses quantifiable, non-invasive, objective, and continuous measurement of physiological and behavioral measures collected through digital devices such as wearables, portable, digestible, or implantable technology. These biomarkers offer valuable insights into disease progression, treatment efficacy, and patient response in real-world settings. The market growth is propelled by advancements in wearable technology, mobile health applications, and AI algorithms that analyze data generated by digital health tools. The ongoing development of digital biomarkers is revolutionizing personalized medicine, remote patient monitoring, and early disease detection, significantly improving healthcare delivery and clinical trial efficiency.
Market Growth Drivers:
The demand for personalized, remote patient care is a significant driver for the digital biomarkers market, enabling a shift towards value-based healthcare models. Real-time tracking of physiological parameters and environmental factors provides a comprehensive health view, allowing for tailored treatment plans and better disease management. Additionally, the use of cutting-edge technology like AI and machine learning (ML) enhances the precision and patient-centricity of clinical trials by capturing real-time data, minimizing site visits, and improving data quality.
Market Restraints:
Challenges include complex reimbursement systems and evolving regulations for digital therapeutics. Uncertainties surrounding reimbursement frameworks can hinder the adoption of digital biomarkers. Navigating regulatory compliance across regions requires robust resources to meet stringent data privacy laws, such as GDPR in Europe and HIPAA in the US. Moreover, standardizing digital biomarkers across various healthcare settings is complicated and may impact their value.
Market Opportunities:
Significant opportunities arise from the use of blockchain for enhanced data security and collaborations with healthcare providers, technology firms, and research institutions. Blockchain technology can protect sensitive health data from breaches, while partnerships accelerate the development of robust biomarkers and foster innovation. These trends support precision medicine by optimizing treatment strategies and improving clinical outcomes.
Key Questions Answered in the Report:
What are the main factors driving the growth of the global Digital Biomarkers Market?
Which therapeutic areas are witnessing the highest adoption of digital biomarkers?
How do regulations and reimbursement policies impact the digital biomarkers market?
Who are the leading players in the Digital Biomarkers Market, and what strategies are they employing to stay competitive?
What are the emerging trends and future outlooks for the global Digital Biomarkers Market?
Competitive Intelligence and Business Strategy:
Key players in the global Digital Biomarkers Market, such as ActiGraph LLC, AliveCor Inc., and Biogen, focus on innovation, strategic partnerships, and product development. Companies are investing in advanced technologies like AI, ML, and blockchain to develop accurate and reliable biomarkers, ensuring compliance with evolving regulatory frameworks. Collaboration with research institutions is critical for maintaining market leadership and addressing healthcare challenges.
Key Companies Profiled:
ActiGraph LLC
AliveCor Inc.
Koneksa Health
Altoida Inc.
Biogen
Empatica Inc.
Vivo Sense
IXICO plc
Aural Analytic
Huma
Sonde Health, Inc.
Digital Biomarkers Market Segmentation
By Component
Data Collection Tools
Data Integration Software
By Therapeutic Area
Cardiovascular and Metabolic Disorders (CVMD)
Neurodegenerative Disorders
Diabetes
Respiratory Disorders
Sleep and Movement Disorders
Others
By Clinical Practice
Diagnostic Digital Biomarkers
Monitoring Digital Biomarkers
Predictive and Prognostic Digital Biomarkers
Others
By End User
Healthcare Consumers
Healthcare Providers
Others
By Region
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa
Table of Contents
1. Executive Summary
1.1. Global Digital Biomarkers Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Product Adoption Analysis
3.2. Technology Assessment
3.3. Regulatory Landscape
3.4. Supply Chain Analysis
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis
4. Price Analysis, 2024A
4.1. Key Highlights
4.2. Key Factors Impacting Therapeutic Area Prices
4.3. Pricing Analysis, By Component
4.4. Regional Prices and Therapeutic Area Preferences
5. Global Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
5.1. Key Highlights
5.1.1. Market Volume (Units) Projections
5.1.2. Market Size (US$ Mn) and Y-o-Y Growth
5.1.3. Absolute $ Opportunity
5.2. Market Size (US$ Mn) Analysis and Forecast
5.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
5.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2031
5.3. Global Digital Biomarkers Market Outlook: Component
5.3.1. Introduction / Key Findings
5.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, By Component, 2019-2023
5.3.3. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
5.3.3.1. Data Collection Tools
5.3.3.1.1. Wearable Devices
5.3.3.1.2. Implantable
5.3.3.1.3. Mobile Applications
5.3.3.1.4. Others
5.3.3.2. Data Integration Software
5.4. Market Attractiveness Analysis: Component
5.5. Global Digital Biomarkers Market Outlook: Therapeutic Area
5.5.1. Introduction / Key Findings
5.5.2. Historical Market Size (US$ Mn) Analysis, By Therapeutic Area, 2019-2023
5.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
5.5.3.1. Cardiovascular and Metabolic Disorders (CVMD)
5.5.3.2. Neurodegenerative Disorders
5.5.3.3. Diabetes
5.5.3.4. Respiratory Disorders
5.5.3.5. Sleep and Movement Disorders
5.5.3.6. Others
5.6. Market Attractiveness Analysis: Therapeutic Area
5.7. Global Digital Biomarkers Market Outlook: Clinical Practice
5.7.1. Introduction / Key Findings
5.7.2. Historical Market Size (US$ Mn) Analysis, By Clinical Practice, 2019-2023
5.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
5.7.3.1. Diagnostic Digital Biomarkers
5.7.3.2. Monitoring Digital Biomarkers
5.7.3.3. Predictive and Prognostic Digital Biomarkers
5.7.3.4. Others
5.8. Market Attractiveness Analysis: Clinical Practice
5.9. Global Digital Biomarkers Market Outlook: End User
5.9.1. Introduction / Key Findings
5.9.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
5.9.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
5.9.3.1. Healthcare Consumers
5.9.3.2. Healthcare Providers
5.9.3.3. Others
5.10. Market Attractiveness Analysis: End User
6. Global Digital Biomarkers Market Outlook: Region
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
6.3.1. North America
6.3.2. Europe
6.3.3. East Asia
6.3.4. South Asia and Oceania
6.3.5. Latin America
6.3.6. Middle East & Africa
6.4. Market Attractiveness Analysis: Region
7. North America Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
7.2.1. By Country
7.2.2. By Component
7.2.3. By Therapeutic Area
7.2.4. By Clinical Practice
7.2.5. By End User
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
7.3.1. U.S.
7.3.2. Canada
7.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
7.4.1. Data Collection Tools
7.4.1.1. Wearable Devices
7.4.1.2. Implantable
7.4.1.3. Mobile Applications
7.4.1.4. Others
7.4.2. Data Integration Software
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
7.5.1. Cardiovascular and Metabolic Disorders (CVMD)
7.5.2. Neurodegenerative Disorders
7.5.3. Diabetes
7.5.4. Respiratory Disorders
7.5.5. Sleep and Movement Disorders
7.5.6. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
7.6.1. Diagnostic Digital Biomarkers
7.6.2. Monitoring Digital Biomarkers
7.6.3. Predictive and Prognostic Digital Biomarkers
7.6.4. Others
7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
7.7.1. Healthcare Consumers
7.7.2. Healthcare Providers
7.7.3. Others
7.8. Market Attractiveness Analysis
8. Europe Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
8.2.1. By Country
8.2.2. By Component
8.2.3. By Therapeutic Area
8.2.4. By Clinical Practice
8.2.5. By End User
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Turkiye
8.3.8. Rest of Europe
8.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
8.4.1. Data Collection Tools
8.4.1.1. Wearable Devices
8.4.1.2. Implantable
8.4.1.3. Mobile Applications
8.4.1.4. Others
8.4.2. Data Integration Software
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
8.5.1. Cardiovascular and Metabolic Disorders (CVMD)
8.5.2. Neurodegenerative Disorders
8.5.3. Diabetes
8.5.4. Respiratory Disorders
8.5.5. Sleep and Movement Disorders
8.5.6. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
8.6.1. Diagnostic Digital Biomarkers
8.6.2. Monitoring Digital Biomarkers
8.6.3. Predictive and Prognostic Digital Biomarkers
8.6.4. Others
8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
8.7.1. Healthcare Consumers
8.7.2. Healthcare Providers
8.7.3. Others
8.8. Market Attractiveness Analysis
9. East Asia Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
9.2.1. By Country
9.2.2. By Component
9.2.3. By Therapeutic Area
9.2.4. By Clinical Practice
9.2.5. By End User
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
9.3.1. China
9.3.2. Japan
9.3.3. South Korea
9.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
9.4.1. Data Collection Tools
9.4.1.1. Wearable Devices
9.4.1.2. Implantable
9.4.1.3. Mobile Applications
9.4.1.4. Others
9.4.2. Data Integration Software
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
9.5.1. Cardiovascular and Metabolic Disorders (CVMD)
9.5.2. Neurodegenerative Disorders
9.5.3. Diabetes
9.5.4. Respiratory Disorders
9.5.5. Sleep and Movement Disorders
9.5.6. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
9.6.1. Diagnostic Digital Biomarkers
9.6.2. Monitoring Digital Biomarkers
9.6.3. Predictive and Prognostic Digital Biomarkers
9.6.4. Others
9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
9.7.1. Healthcare Consumers
9.7.2. Healthcare Providers
9.7.3. Others
9.8. Market Attractiveness Analysis
10. South Asia & Oceania Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
10.2.1. By Country
10.2.2. By Component
10.2.3. By Therapeutic Area
10.2.4. By Clinical Practice
10.2.5. By End User
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
10.3.1. India
10.3.2. Southeast Asia
10.3.3. ANZ
10.3.4. Rest of South Asia & Oceania
10.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
10.4.1. Data Collection Tools
10.4.1.1. Wearable Devices
10.4.1.2. Implantable
10.4.1.3. Mobile Applications
10.4.1.4. Others
10.4.2. Data Integration Software
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
10.5.1. Cardiovascular and Metabolic Disorders (CVMD)
10.5.2. Neurodegenerative Disorders
10.5.3. Diabetes
10.5.4. Respiratory Disorders
10.5.5. Sleep and Movement Disorders
10.5.6. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
10.6.1. Diagnostic Digital Biomarkers
10.6.2. Monitoring Digital Biomarkers
10.6.3. Predictive and Prognostic Digital Biomarkers
10.6.4. Others
10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
10.7.1. Healthcare Consumers
10.7.2. Healthcare Providers
10.7.3. Others
10.8. Market Attractiveness Analysis
11. Latin America Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
11.2.1. By Country
11.2.2. By Component
11.2.3. By Therapeutic Area
11.2.4. By Clinical Practice
11.2.5. By End User
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
11.4.1. Data Collection Tools
11.4.1.1. Wearable Devices
11.4.1.2. Implantable
11.4.1.3. Mobile Applications
11.4.1.4. Others
11.4.2. Data Integration Software
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
11.5.1. Cardiovascular and Metabolic Disorders (CVMD)
11.5.2. Neurodegenerative Disorders
11.5.3. Diabetes
11.5.4. Respiratory Disorders
11.5.5. Sleep and Movement Disorders
11.5.6. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
11.6.1. Diagnostic Digital Biomarkers
11.6.2. Monitoring Digital Biomarkers
11.6.3. Predictive and Prognostic Digital Biomarkers
11.6.4. Others
11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
11.7.1. Healthcare Consumers
11.7.2. Healthcare Providers
11.7.3. Others
11.8. Market Attractiveness Analysis
12. Middle East & Africa Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
12.1. Key Highlights
12.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
12.2.1. By Country
12.2.2. By Component
12.2.3. By Therapeutic Area
12.2.4. By Clinical Practice
12.2.5. By End User
12.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
12.3.1. GCC Countries
12.3.2. Egypt
12.3.3. South Africa
12.3.4. Northern Africa
12.3.5. Rest of Middle East & Africa
12.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
12.4.1. Data Collection Tools
12.4.1.1. Wearable Devices
12.4.1.2. Implantable
12.4.1.3. Mobile Applications
12.4.1.4. Others
12.4.2. Data Integration Software
12.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
12.5.1. Cardiovascular and Metabolic Disorders (CVMD)
12.5.2. Neurodegenerative Disorders
12.5.3. Diabetes
12.5.4. Respiratory Disorders
12.5.5. Sleep and Movement Disorders
12.5.6. Others
12.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
12.6.1. Diagnostic Digital Biomarkers
12.6.2. Monitoring Digital Biomarkers
12.6.3. Predictive and Prognostic Digital Biomarkers
12.6.4. Others
12.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
12.7.1. Healthcare Consumers
12.7.2. Healthcare Providers
12.7.3. Others
12.8. Market Attractiveness Analysis
13. Competition Landscape
13.1. Market Share Analysis, 2024
13.2. Market Structure
13.2.1. Competition Intensity Mapping By Market
13.2.2. Competition Dashboard
13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
13.3.1. ActiGraph LLC
13.3.1.1. Overview
13.3.1.2. Segments and Products
13.3.1.3. Key Financials
13.3.1.4. Market Developments
13.3.1.5. Market Strategy
13.3.2. AliveCor Inc.
13.3.2.1. Overview
13.3.2.2. Segments and Products
13.3.2.3. Key Financials
13.3.2.4. Market Developments
13.3.2.5. Market Strategy
13.3.3. Koneksa Health
13.3.3.1. Overview
13.3.3.2. Segments and Products
13.3.3.3. Key Financials
13.3.3.4. Market Developments
13.3.3.5. Market Strategy
13.3.4. Altoida Inc.
13.3.4.1. Overview
13.3.4.2. Segments and Products
13.3.4.3. Key Financials
13.3.4.4. Market Developments
13.3.4.5. Market Strategy
13.3.5. Biogen
13.3.5.1. Overview
13.3.5.2. Segments and Products
13.3.5.3. Key Financials
13.3.5.4. Market Developments
13.3.5.5. Market Strategy
13.3.6. Empatica Inc.
13.3.6.1. Overview
13.3.6.2. Segments and Products
13.3.6.3. Key Financials
13.3.6.4. Market Developments
13.3.6.5. Market Strategy
13.3.7. Vivo Sense
13.3.7.1. Overview
13.3.7.2. Segments and Products
13.3.7.3. Key Financials
13.3.7.4. Market Developments
13.3.7.5. Market Strategy
13.3.8. IXICO plc
13.3.8.1. Overview
13.3.8.2. Segments and Products
13.3.8.3. Key Financials
13.3.8.4. Market Developments
13.3.8.5. Market Strategy
13.3.9. Aural Analytic
13.3.9.1. Overview
13.3.9.2. Segments and Products
13.3.9.3. Key Financials
13.3.9.4. Market Developments
13.3.9.5. Market Strategy
13.3.10. Huma
13.3.10.1. Overview
13.3.10.2. Segments and Products
13.3.10.3. Key Financials
13.3.10.4. Market Developments
13.3.10.5. Market Strategy
13.3.11. Sonde Health, Inc.
13.3.11.1. Overview
13.3.11.2. Segments and Products
13.3.11.3. Key Financials
13.3.11.4. Market Developments
13.3.11.5. Market Strategy
13.3.12. Akili Interactive Labs, Inc.
13.3.12.1. Overview
13.3.12.2. Segments and Products
13.3.12.3. Key Financials
13.3.12.4. Market Developments
13.3.12.5. Market Strategy
13.3.13. Cambridge Cognition Ltd.
13.3.13.1. Overview
13.3.13.2. Segments and Products
13.3.13.3. Key Financials
13.3.13.4. Market Developments
13.3.13.5. Market Strategy
13.3.14. Dassault Systemes (Medidata)
13.3.14.1. Overview
13.3.14.2. Segments and Products
13.3.14.3. Key Financials
13.3.14.4. Market Developments
13.3.14.5. Market Strategy
13.3.15. Shimmer
13.3.15.1. Overview
13.3.15.2. Segments and Products
13.3.15.3. Key Financials
13.3.15.4. Market Developments
13.3.15.5. Market Strategy
13.3.16. Feel Therapeutics
13.3.16.1. Overview
13.3.16.2. Segments and Products
13.3.16.3. Key Financials
13.3.16.4. Market Developments
13.3.16.5. Market Strategy
13.3.17. Clario
13.3.17.1. Overview
13.3.17.2. Segments and Products
13.3.17.3. Key Financials
13.3.17.4. Market Developments
13.3.17.5. Market Strategy
13.3.18. Imagene AI
13.3.18.1. Overview
13.3.18.2. Segments and Products
13.3.18.3. Key Financials
13.3.18.4. Market Developments
13.3.18.5. Market Strategy
13.3.19. Brainomix
13.3.19.1. Overview
13.3.19.2. Segments and Products
13.3.19.3. Key Financials
13.3.19.4. Market Developments
13.3.19.5. Market Strategy
13.3.20. Kinsa Inc.
13.3.20.1. Overview
13.3.20.2. Segments and Products
13.3.20.3. Key Financials
13.3.20.4. Market Developments
13.3.20.5. Market Strategy
13.3.21. Pfizer Hellas S.A.
13.3.21.1. Overview
13.3.21.2. Segments and Products
13.3.21.3. Key Financials
13.3.21.4. Market Developments
13.3.21.5. Market Strategy
13.3.22. Human API
13.3.22.1. Overview
13.3.22.2. Segments and Products
13.3.22.3. Key Financials
13.3.22.4. Market Developments
13.3.22.5. Market Strategy
13.3.23. Evidation Health, Inc.
13.3.23.1. Overview
13.3.23.2. Segments and Products
13.3.23.3. Key Financials
13.3.23.4. Market Developments
13.3.23.5. Market Strategy
13.3.24. Verily
13.3.24.1. Overview
13.3.24.2. Segments and Products
13.3.24.3. Key Financials
13.3.24.4. Market Developments
13.3.24.5. Market Strategy
13.3.25. electronRx
13.3.25.1. Overview
13.3.25.2. Segments and Products
13.3.25.3. Key Financials
13.3.25.4. Market Developments
13.3.25.5. Market Strategy
14. Appendix
4.1. Research Methodology
4.2. Research Assumptions
4.3. Acronyms and Abbreviations